Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Patients respond well to first study to test higher doses of an anti-cancer drug

13.11.2006
Clinical trial reveals limited side effects and evidence of clinical activity

Researchers in the UK and the United States have found that a drug composed of an antibody carrying a highly toxic anti-cancer agent is well tolerated by patients at much higher doses than have been used before.

The drug, BB-10901 (huN901-DM1), is being tested in a phase I clinical trial in patients who have relapsed or failed to respond to previous treatment for a range of cancers, such as small cell lung cancer (SCLC), other tumours in the lungs of neuroendocrine origin and non-pulmonary small cell carcinomas. Although the trial is not designed to test the efficacy of the drug, researchers report promising clinical responses in patients, including one patient who has remained in remission for more than a year.

Dr Paul Lorigan reported to the EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Prague today (Friday): "The results are important in that, in contrast to a prior regimen investigated in a phase I trial in the United States, significantly higher dose intensity is achieved with the current schedule. This has implications for the design of future trials with this agent, especially as the amount of the drug given is likely to be important in determining clinical response and outcome. In addition, the presence of a durable, complete response as well as other hints of clinical activity are very encouraging.

"The tolerability of this agent compares very favourably with that of standard chemotherapy. The lack of clinically significant bone marrow toxicity by BB-10901 raises the possibility that such an agent could be used either alone or in combination with standard chemotherapy in future clinical trials."

Dr Lorigan, a senior lecturer in medical oncology at the Christie Hospital, Manchester, UK, worked with colleagues in the UK and USA to investigate different dose levels, any adverse effects and how the drug was cleared from the body (pharmacokinetics). The drug, also known as huN901-DM1, is an immunoconjugate – a hybrid molecule specifically designed to deliver a potent cell-killing agent to cancer cells – and is created by attaching a cytotoxic drug DM1 to a monoclonal antibody, huN901. It binds to cells that have the molecule CD56 on their cell surfaces and the DM1 then can kill the cells. Several tumours are CD56 positive, including SCLC, neuroendocrine tumours, Wilms' tumours, and multiple myeloma.

The researchers gave the drug by intravenous infusions for three consecutive days every three weeks. The researchers initially enrolled four patients at each dose level (4, 8, 16, 24, 36, 48, 60, 75 milligrams per squared metre of body surface area (mg/m2)). When a patient experienced a dose-limiting toxicity the cohort was enlarged to six patients at that dose. So far, 40 patients have been treated.

Adverse effects were seen in six patients and included constipation, fatigue, leg pain, headache, inflamed pancreas, hypotension and myocardial infarction. Dr Lorigan said: "In general, the study drug was well tolerated, particularly when compared to standard chemotherapy. There was no clinically significant myelosuppression, most probably because the immunoconjugate is targeted at the tumour rather than the normal cells. Also, there was no clinical evidence of serious allergic or infusion reactions. The one side effect we have seen at higher doses is headache. This seems to be reduced if we increase the infusion time, and it may respond to other medication given with the study drug – we are investigating this further."

One patient with metastatic, recurrent Merkel cell carcinoma (a rare, aggressive cancer that develops on, or just beneath, the skin and in hair follicles) had a durable, complete response and remains in clinical remission more than a year after treatment. "This patient had numerous prior relapses and had failed standard chemotherapy," said Dr Lorigan. Eight patients had stable disease lasting between six and 21 weeks.

"It is difficult to draw any reliable conclusions from an early phase study such as this, but we are encouraged to see early signs of activity. While some tumours treated were indolent, others such as extensive SCLC were very aggressive. The presence of stable disease in a patient with SCLC over six cycles of therapy is very encouraging," he continued.

Pharmacokinetics showed that drug was able to tackle tumour cells expressing CD56 more effectively at the higher doses. The researchers have not reached the maximum tolerated dose yet and are continuing to enrol new patients.

"We are considering amending the protocol and adding three patients at 75 mg/m2/day, with pre-medication prior to infusions of BB-10901. While we have not seen dose-limiting toxicity at this level with the slower infusion (without pre-medication), we have seen headache in two patients, which is a moderate adverse effect. We anticipate that pre-medication will ameliorate or prevent this symptom. If well tolerated, we would then increase the dose to 94 mg/m2/day," said Dr Lorigan.

He concluded: "Treatment options for these patients are limited and we are encouraged by the early results with this novel agent. We are grateful to the patients, their families, the investigators, clinical staff, and our colleagues at ImmunoGen (the sponsor of the clinical study) for their participation and continued support of this trial."

Emma Mason | EurekAlert!
Further information:
http://www.eortc.org

More articles from Studies and Analyses:

nachricht The importance of biodiversity in forests could increase due to climate change
17.11.2017 | Deutsches Zentrum für integrative Biodiversitätsforschung (iDiv) Halle-Jena-Leipzig

nachricht Win-win strategies for climate and food security
02.10.2017 | International Institute for Applied Systems Analysis (IIASA)

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

Im Focus: Researchers Develop Data Bus for Quantum Computer

The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.

Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...

Im Focus: Wrinkles give heat a jolt in pillared graphene

Rice University researchers test 3-D carbon nanostructures' thermal transport abilities

Pillared graphene would transfer heat better if the theoretical material had a few asymmetric junctions that caused wrinkles, according to Rice University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

NASA detects solar flare pulses at Sun and Earth

17.11.2017 | Physics and Astronomy

NIST scientists discover how to switch liver cancer cell growth from 2-D to 3-D structures

17.11.2017 | Health and Medicine

The importance of biodiversity in forests could increase due to climate change

17.11.2017 | Studies and Analyses

VideoLinks
B2B-VideoLinks
More VideoLinks >>>